全文获取类型
收费全文 | 8696篇 |
免费 | 633篇 |
国内免费 | 181篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 115篇 |
妇产科学 | 33篇 |
基础医学 | 729篇 |
口腔科学 | 807篇 |
临床医学 | 1017篇 |
内科学 | 812篇 |
皮肤病学 | 59篇 |
神经病学 | 27篇 |
特种医学 | 126篇 |
外科学 | 287篇 |
综合类 | 1266篇 |
现状与发展 | 1篇 |
预防医学 | 2574篇 |
眼科学 | 76篇 |
药学 | 1192篇 |
7篇 | |
中国医学 | 251篇 |
肿瘤学 | 93篇 |
出版年
2024年 | 15篇 |
2023年 | 103篇 |
2022年 | 218篇 |
2021年 | 467篇 |
2020年 | 291篇 |
2019年 | 275篇 |
2018年 | 213篇 |
2017年 | 226篇 |
2016年 | 432篇 |
2015年 | 486篇 |
2014年 | 679篇 |
2013年 | 748篇 |
2012年 | 675篇 |
2011年 | 743篇 |
2010年 | 512篇 |
2009年 | 403篇 |
2008年 | 342篇 |
2007年 | 413篇 |
2006年 | 315篇 |
2005年 | 276篇 |
2004年 | 253篇 |
2003年 | 203篇 |
2002年 | 144篇 |
2001年 | 144篇 |
2000年 | 121篇 |
1999年 | 95篇 |
1998年 | 80篇 |
1997年 | 74篇 |
1996年 | 63篇 |
1995年 | 57篇 |
1994年 | 61篇 |
1993年 | 70篇 |
1992年 | 51篇 |
1991年 | 37篇 |
1990年 | 42篇 |
1989年 | 22篇 |
1988年 | 19篇 |
1987年 | 26篇 |
1986年 | 6篇 |
1985年 | 11篇 |
1984年 | 14篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 9篇 |
1976年 | 11篇 |
1974年 | 4篇 |
排序方式: 共有9510条查询结果,搜索用时 15 毫秒
61.
Rebecca Nzawa Soko Rachael M. Burke Helena R.A. Feasey Wakumanya Sibande Marriott Nliwasa Marc Y.R. Henrion McEwen Khundi Peter J. Dodd Chu Chang Ku Gift Kawalazira Augustine T. Choko Titus H. Divala Elizabeth L. Corbett Peter MacPherson 《Emerging infectious diseases》2021,27(7):1831
The coronavirus disease (COVID-19) pandemic might affect tuberculosis (TB) diagnosis and patient care. We analyzed a citywide electronic TB register in Blantyre, Malawi and interviewed TB officers. Malawi did not have an official COVID-19 lockdown but closed schools and borders on March 23, 2020. In an interrupted time series analysis, we noted an immediate 35.9% reduction in TB notifications in April 2020; notifications recovered to near prepandemic numbers by December 2020. However, 333 fewer cumulative TB notifications were received than anticipated. Women and girls were affected more (30.7% fewer cases) than men and boys (20.9% fewer cases). Fear of COVID-19 infection, temporary facility closures, inadequate personal protective equipment, and COVID-19 stigma because of similar symptoms to TB were mentioned as reasons for fewer people being diagnosed with TB. Public health measures could benefit control of both TB and COVID-19, but only if TB diagnostic services remain accessible and are considered safe to attend. 相似文献
62.
Paenibacillus thiaminolyticus is a nonvirulent organism found in human and ruminant microbiota. However, P. thiaminolyticus can act as an opportunistic pathogen in humans. We describe a case of abdominal wall hematoma secondarily infected by P. thiaminolyticus. Our findings emphasize the risk for unusual Paenibacillus infections in otherwise healthy persons. 相似文献
63.
Anselme Millogo Ahmed Loukil Coralie LOllivier Diakourga Arthur Djibougou Sylvain Godreuil Michel Drancourt 《Emerging infectious diseases》2021,27(6):1758
Mycobacterium leprae was detected by optical microscopy, fluorescent in situ hybridization, and molecular detection in feces collected for the diagnosis of Entamoeba coli enteritis in a leprosy patient in Burkina Faso. This observation raises questions about the role of fecal excretion of M. leprae in the natural history and diagnosis of leprosy. 相似文献
64.
全国细菌耐药监测网 《中国感染控制杂志》2021,20(1):53-60
目的探讨全国尿标本分离细菌菌种分布及耐药变迁。方法按照全国细菌耐药监测网(CARSS)技术方案,应用WHONET5.6软件对2014—2019年所有CARSS成员单位上报的尿标本分离细菌及药敏结果数据进行分析。结果男性患者尿标本分离细菌居前5位者分别为大肠埃希菌(33.1%~34.6%)、粪肠球菌(9.2%~10.2%)、肺炎克雷伯菌(9.0%~9.4%)、屎肠球菌(7.8%~10.2%)和铜绿假单胞菌(5.6%~6.9%),女性患者尿标本分离细菌居前5位者分别为大肠埃希菌(57.0%~57.4%)、肺炎克雷伯菌(7.5%~8.3%)、屎肠球菌(6.8%~8.7%)、粪肠球菌(5.5%~6.0%)和奇异变形杆菌(3.3%~3.5%)。男性和女性患者尿标本分离粪肠球菌对氨苄西林和呋喃妥因耐药率分别<12%和7%,对万古霉素耐药率<3%;屎肠球菌对氨苄西林、左氧氟沙星耐药率均为90%左右,对万古霉素耐药率<4%。大肠埃希菌对头孢曲松耐药率>47%,对头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、呋喃妥因耐药率≤8%,对于β-内酰胺类耐药率男性比女性高,其中头孢曲松的耐药率高12个百分点左右。男性患者分离肺炎克雷伯菌对头孢曲松耐药率为58%左右,女性患者耐药率为45%左右。男性和女性患者尿标本分离铜绿假单胞菌对头孢哌酮/舒巴坦和哌拉西林/他唑巴坦的耐药率均<14%,对碳青霉烯类耐药率为15%左右。鲍曼不动杆菌对头孢哌酮/舒巴坦和米诺环素耐药率分别<27%和22%,对碳青霉烯类耐药率,男性为31.7%~47.7%,女性为26.5%~41.2%。结论尿标本分离细菌在不同性别构成上有所不同,且部分肠杆菌目细菌耐药率不同性别间也有一定差异,不同年度间部分细菌的耐药率也有一定变化。尿标本分离细菌的耐药监测,可为尿路感染抗菌药物合理应用提供参考数据。 相似文献
65.
目的分析脊柱术后医院感染患者病原菌分布特征及中性粒细胞64(CD64)和中性粒细胞百分比(NEU%)表达情况。方法选取2017年6月-2019年6月天津市天津医院收治的脊柱术后医院感染患者51例为感染组,并选取同期于医院就诊的脊柱术后未发生感染患者51例为未感染组。分析感染组患者病原菌情况,检测患者NEU和CD64水平;ROC曲线分析CD64和NEU%指标水平预测感染的诊断价值。结果 51例感染患者共培养分离病原菌78株,其中革兰阴性菌42株(53.85%)、革兰阳性菌33株(42.31%)、真菌3株(3.85%),以铜绿假单胞菌及金黄色葡萄球菌为主。术后7 d,感染组体温、WBC、中性粒细胞计数、CRP、ESR分别为(38.47±0.52)℃、(8.34±2.17)×109/L、(5.98±1.94)×109/L、(54.52±19.93)mg/L、(51.74±21.88)mm/h均高于非感染组(P<0.05)。术后7 d,感染组CD64、NEU%分别为(8.87±2.13)%、(84.93±13.39)高于非感染组(P<0.05)。CD64指数与NEU%水平诊断ROC曲线下面积分别为0.922、0.826。结论脊柱术后医院感染以革兰阴性菌为主,CD64及NEU%水平有助于脊柱术后医院感染的早期诊断。 相似文献
66.
Sarah A. Collier Li Deng Elizabeth A. Adam Katharine M. Benedict Elizabeth M. Beshearse Anna J. Blackstock Beau B. Bruce Gordana Derado Chris Edens Kathleen E. Fullerton Julia W. Gargano Aimee L. Geissler Aron J. Hall Arie H. Havelaar Vincent R. Hill Robert M. Hoekstra Sujan C. Reddy Elaine Scallan Erin K. Stokes Jonathan S. Yoder Michael J. Beach 《Emerging infectious diseases》2021,27(1):140
Provision of safe drinking water in the United States is a great public health achievement. However, new waterborne disease challenges have emerged (e.g., aging infrastructure, chlorine-tolerant and biofilm-related pathogens, increased recreational water use). Comprehensive estimates of the health burden for all water exposure routes (ingestion, contact, inhalation) and sources (drinking, recreational, environmental) are needed. We estimated total illnesses, emergency department (ED) visits, hospitalizations, deaths, and direct healthcare costs for 17 waterborne infectious diseases. About 7.15 million waterborne illnesses occur annually (95% credible interval [CrI] 3.88 million–12.0 million), results in 601,000 ED visits (95% CrI 364,000–866,000), 118,000 hospitalizations (95% CrI 86,800–150,000), and 6,630 deaths (95% CrI 4,520–8,870) and incurring US $3.33 billion (95% CrI 1.37 billion–8.77 billion) in direct healthcare costs. Otitis externa and norovirus infection were the most common illnesses. Most hospitalizations and deaths were caused by biofilm-associated pathogens (nontuberculous mycobacteria, Pseudomonas, Legionella), costing US $2.39 billion annually. 相似文献
67.
Connie A. Haley Patricia Macias Supriya Jasuja Betsy A. Jones Marie-Claire Rowlinson Roshni Jaimon Pennelyn Onderko Elaine Darnall Maria E. Gomez Charles Peloquin David Ashkin Neela D. Goswami 《Emerging infectious diseases》2021,27(1):332
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose. 相似文献
68.
Julie Bennett Jane Zhang William Leung Susan Jack Jane Oliver Rachel Webb Nigel Wilson Dianne Sika-Paotonu Matire Harwood Michael G. Baker 《Emerging infectious diseases》2021,27(1):36
We describe trends in acute rheumatic fever (ARF), rheumatic heart disease (RHD), and RHD deaths among population groups in New Zealand. We analyzed initial primary ARF and RHD hospitalizations during 2000–2018 and RHD mortality rates during 2000–2016. We found elevated rates of initial ARF hospitalizations for persons of Māori (adjusted rate ratio [aRR] 11.8, 95% CI 10.0–14.0) and Pacific Islander (aRR 23.6, 95% CI 19.9–27.9) ethnicity compared with persons of European/other ethnicity. We also noted higher rates of initial RHD hospitalization for Māori (aRR 3.2, 95% CI 2.9–3.5) and Pacific Islander (aRR 4.6, 95% CI 4.2–5.1) groups and RHD deaths among these groups (Māori aRR 12.3, 95% CI 10.3–14.6, and Pacific Islanders aRR 11.2, 95% CI 9.1–13.8). Rates also were higher in socioeconomically disadvantaged neighborhoods. To curb high rates of ARF and RHD, New Zealand must address increasing social and ethnic inequalities. 相似文献
69.
Federica Gigliucci Angela H.A.M. van Hoek Paola Chiani Arnold Knijn Fabio Minelli Gaia Scavia Eelco Franz Stefano Morabito Valeria Michelacci 《Emerging infectious diseases》2021,27(3):853
Shiga toxin–producing Escherichia coli (STEC) O80:H2 has emerged in Europe as a cause of hemolytic uremic syndrome associated with bacteremia. STEC O80:H2 harbors the mosaic plasmid pR444_A, which combines several virulence genes, including hlyF and antimicrobial resistance genes. pR444_A is found in some extraintestinal pathogenic E. coli (ExPEC) strains. We identified and characterized 53 STEC strains with ExPEC-associated virulence genes isolated in Italy and the Netherlands during 2000–2019. The isolates belong to 2 major populations: 1 belongs to sequence type 301 and harbors diverse stx2 subtypes, the intimin variant eae-ξ, and pO157-like and pR444_A plasmids; 1 consists of strains belonging to various sequence types, some of which lack the pO157 plasmid, the locus of enterocyte effacement, and the antimicrobial resistance–encoding region. Our results showed that STEC strains harboring ExPEC-associated virulence genes can include multiple serotypes and that the pR444_A plasmid can be acquired and mobilized by STEC strains. 相似文献
70.
Amyn A. Malik Neel R. Gandhi Timothy L. Lash Lisa M. Cranmer Saad B. Omer Junaid F. Ahmed Sara Siddiqui Farhana Amanullah Aamir J. Khan Salmaan Keshavjee Hamidah Hussain Mercedes C. Becerra 《Emerging infectious diseases》2021,27(3):805
In Karachi, Pakistan, a South Asian megacity with a high prevalence of tuberculosis (TB) and low HIV prevalence, we assessed the effectiveness of fluoroquinolone-based preventive therapy for drug-resistant (DR) TB exposure. During February 2016–March 2017, high-risk household contacts of DR TB patients began a 6-month course of preventive therapy with a fluoroquinolone-based, 2-drug regimen. We assessed effectiveness in this cohort by comparing the rate and risk for TB disease over 2 years to the rates and risks reported in the literature. Of 172 participants, TB occurred in 2 persons over 336 person-years of observation. TB disease incidence rate observed in the cohort was 6.0/1,000 person-years. The incidence rate ratio ranged from 0.29 (95% CI 0.04–1.3) to 0.50 (95% CI 0.06–2.8), with a pooled estimate of 0.35 (95% CI 0.14–0.87). Overall, fluoroquinolone-based preventive therapy for DR TB exposure reduced risk for TB disease by 65%. 相似文献